Abstract
Hammerman and colleagues have shown that the Pim-2 kinase is required to confer rapamycin resistance in hematopoietic cells, thus providing a strong rationale for the development of Pim kinase inhibitors as potential therapeutic agents in hematologic malignancies.
Original language | English (US) |
---|---|
Pages (from-to) | 4158-4159 |
Number of pages | 2 |
Journal | Blood |
Volume | 105 |
Issue number | 11 |
DOIs | |
State | Published - Jun 1 2005 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology